MaxIntel® Pharmacy Trend Alert
Background & Medication Details1,2
§ Rosuvastatin, generic Crestor®, entered the market May 5, 2016.
§ Rosuvastatin belongs to the class of medications commonly referred to as “statins”.
Anticipated Market Impact1,2
§ Lipitor®, the bestselling drug in history, has become the preferred statin of choice after its generic, atorvastatin, was released on to the market. However, Crestor® (rosuvastatin), the most potent statin on the market, is anticipated to become the preferred high-intensity statin for physicians and patients.
§ Watson, the manufacturer of rosuvastatin, is anticipated to have a 67 day exclusivity period, which is much shorter compared to the typical 180 day exclusivity period most first time generic manufacturers receive. During this exclusivity period the price remains high as there is minimal competition. However, by early July, multiple generic manufacturers are expected to enter the market, drastically decreasing the price of generic rosuvastatin. Below is a projected timeline of rosuvastatin’s price reduction based on atorvastatin’s historical sales data.
MaxCare Management Options
Rosuvastatin is anticipated to quickly become another low cost, first line option for patients with high cholesterol and will be incorporated into MaxCare’s Clinical Management programs to maximize cost effective use of high cost branded medications such as the new PCSK-9 inhibitors (Praluent® and Repatha®) as well as the remaining branded cholesterol reduction medications (Livalo®, Vytorin®, or Zetia®).
For more clinical solutions, please contact MaxCare and request a consultation with the MaxCare Clinical Department.
1FDA approves first generic Crestor. U.S. FDA. Available online at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498373.htm Last updated 4/29/2016. Last accessed 5/23/2016
2Larry Husten. Experts Foresee Major Role for Generic Crestor. CardioBrief. Available online at: http://cardiobrief.org/2016/05/02/experts-foresee-major-role-for-generic-crestor/ Last Updates 5/2/2016. Last accessed 5/23/2016.